• EORTC Patient recruitment Metastatic Melanoma
    Categories: ,

    EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma

    5 Aug 2022

  • Dr Martin Charles Mihm
    Categories: ,

    In Memoriam: Dr Martin Charles Mihm

    27 Jul 2022

  • Melanoma
    Categories: ,

    Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma

    24 May 2022

  • Melanoma
    Categories: , ,

    PRESS RELEASE: European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients

    29 Jun 2021

  • Melanoma
    Categories: ,

    EORTC Melanoma Group changing daily practice for cancer patients

    28 Sep 2020

  • A. Eggermont - ESMO 2020
    Categories: , ,

    PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma

    19 Sep 2020

  • Presentation A. Eggermont at ASCO 2020
    Categories: ,

    EORTC 1325-MG/Keynote 054: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results at three-year median follow-up

    29 May 2020

  • ASCO19 - 18071 study - Prof. Eggermont
    Categories: ,

    Sustained long term survival benefit with adjuvant ipilimumab in patients with high risk stage III melanoma

    1 Jun 2019